(Total Views: 864)
Posted On: 11/16/2025 10:31:33 PM
Post# of 158771
One small correction of Ken's transcript of the Lalezari interview with Karen Jagoda!
His transcript reads -
Karen Jagoda: Yes, I've always wondered about the drug manufacturers who are designing these drugs that don't work for a small portion of the population.
What she actually said that got me excited was -
Yes, I've always wondered about the drug manufacturers who are designing these drugs that don't work WITH BUT a small portion of the population.
As I have noted before, for some cancers, ICIs by themselves have a pretty miserable response rate. For mTNBC, it is less than 10%. But once Leronlimab turns cold tumors HOT, the response rate is 88% or, hopefully, better!
Now that's worth getting excited about!
Leronlimab flips the script!
His transcript reads -
Karen Jagoda: Yes, I've always wondered about the drug manufacturers who are designing these drugs that don't work for a small portion of the population.
What she actually said that got me excited was -
Yes, I've always wondered about the drug manufacturers who are designing these drugs that don't work WITH BUT a small portion of the population.
As I have noted before, for some cancers, ICIs by themselves have a pretty miserable response rate. For mTNBC, it is less than 10%. But once Leronlimab turns cold tumors HOT, the response rate is 88% or, hopefully, better!
Now that's worth getting excited about!
Leronlimab flips the script!
(28)
(0)
